Charles Shapiro L MD

Charles Shapiro L MD
ProfessorCollege of Medicineshapiro.73@osu.edu
B405 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-6401Fax: (614) 293-7529
  • Cancer Control

Current Publications

  • Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Garzon ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corrà F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CMPluripotent Stem Cell miRNAs and Metastasis in Invasive Breast Cancer.J Natl Cancer Inst 106 12/1/2014
  • Derry HM, Jaremka LM, Bennett JM, Peng J, Andridge R, Shapiro C, Malarkey WB, Emery CF, Layman R, Mrozek E, Glaser R, Kiecolt-Glaser JKYoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial.Psychooncology in press 10/21/2014
  • Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL, Chen CSAMPK Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Akt-MDM2-Foxo3a Signaling Axis.Cancer Res 74 4783-95 9/1/2014
  • Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CLPhase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.Clin Breast Cancer 14 228-34 8/1/2014
  • Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EPComparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance).J Clin Oncol 32 2311-7 8/1/2014
  • Lu J, Das M, Kanji S, Aggarwal R, Joseph M, Ray A, Shapiro CL, Pompili VJ, Das HInduction of ATM/ATR pathway combined with Vγ2Vδ2 T cells enhances cytotoxicity of ovarian cancer cells.Biochim Biophys Acta 1842 1071-9 7/1/2014
  • Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy BA Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.Invest New Drugs in press 6/5/2014
  • Wesolowski R, Abdel-Rasoul M, Lustberg M, Paskell M, Shapiro CL, Macrae ERTreatment-related mortality with everolimus in cancer patients.Oncologist 19 661-8 6/1/2014
  • Mita MM, Joy AA, Mita A, Sankhala K, Jou YM, Zhang D, Statkevich P, Zhu Y, Yao SL, Small K, Bannerji R, Shapiro CLRandomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.Clin Breast Cancer 14 169-76 6/1/2014
  • Harshman SW, Hoover ME, Huang C, Branson OE, Chaney SB, Cheney CM, Rosol TJ, Shapiro CL, Wysocki VH, Huebner K, Freitas MAHistone h1 phosphorylation in breast cancer.J Proteome Res 13 2453-67 5/2/2014
  • Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, Carpenter J, Chang-Claude J, Martin NG, Montgomery GW, Kristensen V, Anton-Culver H, Goodfellow P, Tapper WJ, Rafiq S, Clarke C, Pathmanathan N, Rudolph A, Flesch-Janys D, Nickels S, Olson JE, Ingle JN, Olswold C, Slettedahl S, Eckel-Passow JE, Anderson SK, Visscher DW, Cafourek VL, Sicotte H, Prodduturi N, Weiderpass E, Bernstein L, Ziogas A, Ivanovich J, Giles GG, Baglietto L, Southey M, Kosma VM, Fischer HP, GENICA Network, Reed MW, Mannermaa A, Easton D, Hall P, Brauch H, Cox A, Zheng W, Godwin AK, Hamann U, Ambrosone C, Toland AE, Nevanlinna H, Vachon CM, Couch FJ, Gerty SM, Durcan L, Konstantopoulou I, Fostira F, Vratimos A, Apostolou P, Konstanta I, Kotoula V, Lakis S, Dimopoulos MA, Skarlos D, Pectasides D, Fountzilas G, Beckmann MW, Hein A, Ruebner M, Ekici AB, Hartmann A, Schulz-Wendtland R, Renner SP, Janni W, Rack B, Scholz C, Neugebauer J, Andergassen U, Lux MP, Haeberle L, Cross SS, Deming-Halverson S, Shrubsole M, Cai Q, Shu XO, Daly M, Weaver J, Ross E, Klemp J, Sharma P, Torres D, Rüdiger T, Wölfing H, Ulmer HU, Försti A, Khoury T, Kumar S, Pilarski R, Shapiro CL, Greco D, Heikkilä P, Aittomäki K, Blomqvist C, Irwanto A, Liu J, Pankratz VS, Wang X, Severi GGenome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.Carcinogenesis 35 1012-9 5/1/2014
  • Kiecolt-Glaser JK, Bennett JM, Andridge R, Peng J, Shapiro CL, Malarkey WB, Emery CF, Layman R, Mrozek EE, Glaser RYoga's impact on inflammation, mood, and fatigue in breast cancer survivors: a randomized controlled trial.J Clin Oncol 32 1040-9 4/1/2014
  • Palmieri D, Costinean S, Shapiro CL, Huebner K, Croce CM, Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, Carasi SProtective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.Proc Natl Acad Sci U S A 111 4536-41 3/25/2014
  • Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, Huebner KmicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.Oncotarget 5 1174-84 3/15/2014
  • Borden CP, Shapiro CL, Ramirez MT, Kotur L, Farrar WQuality improvement in breast cancer project: compliance with antiresorptive agents and changing patterns of drug use.J Natl Compr Canc Netw 12 Suppl 1 S33-5 2/1/2014
  • Paisie C, Lovat F, Morrison C, Zhang J, Scarpa A, Croce CM, Shapiro CL, Huebner K, Gasparini P, Fassan M, Cascione L, Guler G, Balci S, Irkkan CAndrogen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.PLoS One 9 e88525 1/1/2014
  • Post DM, Shapiro CL, Cegala DJ, David P, Katz ML, Krok JL, Phillips GS, McAlearney AS, Lehman JS, Hicks W, Paskett EDImproving symptom communication through personal digital assistants: the CHAT (Communicating Health Assisted by Technology) project.J Natl Cancer Inst Monogr 2013 153-61 12/1/2013
  • Doo L, Shapiro CLSkeletal manifestations of treatment of breast cancer on premenopausal women.Curr Osteoporos Rep 11 311-8 12/1/2013
  • Wu L, de Bruin A, Wang H, Simmons T, Cleghorn W, Goldenberg LE, Sites E, Sandy A, Trimboli A, Fernandez SA, Eng C, Shapiro C, Leone GSelective roles of E2Fs for ErbB2- and Myc-mediated mammary tumorigenesis.Oncogene in press 11/25/2013
  • Aggarwal R, Lu J, Kanji S, Das M, Joseph M, Lustberg MB, Ray A, Pompili VJ, Shapiro CL, Das HHuman Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors.Int J Cancer 133 2133-44 11/1/2013
  • Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski RDocetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.Support Care Cancer 21 2679-86 10/1/2013
  • Mrozek E, Flynn JM, Shapiro CL, Layman RM, Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy BPilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.Support Care Cancer 21 2845-51 10/1/2013
  • Shapiro CL, Mrózek E, Povoski SPThe challenges of individualized care for older patients with localized breast cancer.Expert Rev Anticancer Ther 13 963-73 8/1/2013
  • Shapiro CLBisphosphonate-related osteonecrosis of jaw in the adjuvant breast cancer setting: risks and perspective.J Clin Oncol 31 2648-50 7/20/2013
  • Huang K, Wang C, Pécot T, Zynger DL, Machiraju R, Shapiro CLIdentifying survival associated morphological features of triple negative breast cancer using multiple datasets.J Am Med Inform Assoc 20 680-7 7/1/2013
  • McConoughey SJ, Jalgaonkar SP, Leon M, Merchant AS, Dominick JL, Yin X, Wolford CC, Chang Y, Zmuda EJ, O'Toole SA, Millar EK, Roller SL, Shapiro CL, Ostrowski MC, Sutherland RL, Hai TTranscription factor ATF3 links host adaptive response to breast cancer metastasis.J Clin Invest 123 2893-906 7/1/2013
  • Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CLIncidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.Ann Oncol 24 1526-33 6/1/2013
  • Byrd JC, Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Volinia S, Shapiro CL, Freitas MA, Croce CMIn vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.J Exp Med 210 951-68 5/6/2013
  • Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CLSevere and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.Cancer Chemother Pharmacol 71 1183-90 5/1/2013
  • Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL, Alliance for Clinical Trials in OncologyEffect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.JAMA 309 1359-67 4/3/2013
  • Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161 156-64 3/1/2013
  • Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner KIntegrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.PLoS One 8 e55910 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu